The Kadota Fund International Forum 2004—Clinical group consensus

J. van der Zee a; Z. Vujaskovic b; M. Kondo c; T. Sugahara d

a Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, the Netherlands
b Duke University Medical Center, Durham, USA
c AINO Hospital, Osaka, Japan
d Kyoto University, Kyoto, Japan

Online Publication Date: 01 January 2008


To link to this Article: DOI: 10.1080/02656730801895058
URL: http://dx.doi.org/10.1080/02656730801895058

Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.
Part I. Clinical Hyperthermia

The Kadota Fund International Forum 2004 – Clinical group consensus*

J. VAN DER ZEE¹, Z. VUJASKOVIC², M. KONDO³, & T. SUGAHARA⁴

¹Erasmus MC – Daniel den Hoed Cancer Center, Rotterdam, the Netherlands, ²Duke University Medical Center, Durham, USA, ³AINO Hospital, Osaka, Japan, and ⁴Kyoto University, Kyoto, Japan

(Received 29 June 2007; revised 28 November 2007; accepted 4 January 2008)

Abstract

The results from experimental studies indicate that hyperthermia is both an effective complementary treatment to, and a strong sensitizer of, radiotherapy and many cytotoxic drugs. Since the first international hyperthermia conference in 1975, Washington DC, techniques to increase tumour temperature have been developed and tested clinically. Hyperthermia can be applied by several methods: local hyperthermia by external or internal energy sources, perfusion hyperthermia of organs, limbs, or body cavities, and whole body hyperthermia. The clinical value of hyperthermia in combination with other treatment modalities has been shown by randomised trials. Significant improvement in clinical outcome has been demonstrated for tumours of the head and neck, breast, brain, bladder, cervix, rectum, lung, oesophagus, for melanoma and sarcoma. The addition of hyperthermia resulted in remarkably higher (complete) response rates, accompanied by improved local tumour control rates, better palliative effects, and/or better overall survival rates. Toxicity from hyperthermia cannot always be avoided, but is usually of limited clinical relevance. In spite of these good clinical results, hyperthermia has received little attention. Problems with acceptance concern the limited availability of equipment, the lack of awareness concerning clinical results, and the lack of financial resources. In this paper the most relevant literature describing the clinical effects of hyperthermia is reviewed and discussed, and means to overcome the lack of awareness and use of this modality is described.

Keywords: Hyperthermia, clinical results, level I evidence, review, acceptance of treatment

General introduction

Hyperthermia is the elevation of temperature above the physiological level with the objective to achieve therapeutic gain. Hyperthermia is generally defined as a modest elevation of temperature to a range of 39 to 45°C. Higher temperatures are used for thermal ablation. Only clinicians using classical hyperthermia participated in the Kadota meeting; therefore, this report is limited to the use of temperatures in the range of 39°C to 45°C.

The use of elevated temperatures for the treatment of cancer has been well documented for centuries [1].

The first international congress on hyperthermic oncology held in 1975 in Washington DC ignited worldwide interest in hyperthermia. As with most new treatment modalities, hyperthermia was initially met with ever increasing enthusiasm reflected by an exponential increase in the number of papers and participants at meetings. Interest in hyperthermia waned thereafter due to disappointing clinical results of the first randomised studies in the USA, accompanied by reluctant sponsoring authorities and hospital boards concerned over support of future research.

However, more recent results of several randomised studies have shown great improvement...
in treatment outcome by the addition of hyperthermia to radiotherapy or chemotherapy, provided adequate heating procedures are used. Nevertheless, this treatment modality has failed to garner broad acceptance. In this report, the consensus of the participants at the Kadota forum on clinical aspects of hyperthermia are summarised and the problems involved in gaining acceptance, along with ways to overcome these problems, are discussed.

Methods to increase tumour temperatures

Clinical hyperthermia is achieved by exposing tissues to conductive heat sources, or non-ionising radiation (e.g. electromagnetic or ultrasonic fields). Although these modalities deposit energy in tissue by different physical mechanisms, they have general similarities. They are sensitive to the heterogeneity of tissue properties, geometry of blood flow, and the practical problems of coupling the energy source into tissue. Hyperthermia can be administered either invasively, or noninvasively using externally applied power. It can be delivered locally, by perfusion or as a whole body hyperthermia (Figure 1).

Local hyperthermia

The aim of local hyperthermia is to achieve the optimal thermal dose in the tumour tissue without exceeding the tolerance limits of the surrounding normal tissues. Local hyperthermia can be applied by external, intraluminal or interstitial methods. Electromagnetic or ultrasound energy is directed at the treatment volume. The volume that can be heated depends on the physical characteristics of the energy source and on the type of applicator (array) [2]. Methods to apply hyperthermia externally can be divided into superficial and deep techniques. For deep heating, the energy is directed from around the part of the body in which the target volume is located. The energy distribution within the tissues is strongly dependent on tissue characteristics and thereby is inhomogeneous. The temperature variance is not simply a result of the energy distribution, but also depends on thermal tissue characteristics and blood flow. During local hyperthermia, the systemic temperature may increase as well, depending on both the heated volume and the measures taken to help the patient lose energy.

Perfusion hyperthermia

Perfusion of a limb, organ, or body cavity with heated fluids produces regional heating [3, 4]. When this approach is applied to limbs, and without a cytotoxic agent, the temperature can be safely increased to about 43°C for a duration of two hours. When used in combination with cytotoxic drugs, the perfusion fluid temperature should be adjusted to avoid unacceptable toxicity.

Whole-body hyperthermia

For whole-body hyperthermia, several methods have been used. A common characteristic is the
introduction of energy into the body, while at the same time energy losses are minimised. The temperature increase is usually limited to 41.8°C–42°C. Experience with radiant heat methods, for which the patients need deep sedation during the treatment, has shown that this procedure is well tolerated [5, 6]. A newer approach is to increase the temperature to about 40°C for a long duration, which, in combination with cytokines and/or cytotoxic drugs is expected to lead to a greater therapeutic index than whole-body hyperthermia at the maximum tolerated level for a short duration [7].

Clinical studies

In order to gain wide acceptance as a new treatment modality, hyperthermia has to fulfil the following criteria:

1. It has to be necessary – i.e. there must exist a need for improvement in treatment outcome over standard treatment;
2. It has to be effective – the effectiveness of the treatment needs to be shown in preclinical and clinical studies;
3. It has to be efficient: results should show a favourable balance between cost and effect.

The treatment must result in improvements which are relevant to the patient. In this respect, endpoints are distinguished into ‘surrogate’ and ‘true’ endpoints. True endpoints are relevant to the patient, such as palliation, an improved quality of life, or longer survival. Surrogate endpoints are defined as response rate and improvement in laboratory results, so long as these indications of treatment effect do not coincide with improvement of true endpoints.

The quality of evidence from clinical studies, which may lead to acceptance of a new treatment modality, has been grouped to the following three levels.

Level 1. Evidence obtained from at least one properly randomised controlled clinical trial;
Level 2-1. Evidence obtained from well-designed controlled trials without randomisation;
Level 2-2. Evidence obtained from well-designed cohort or case-control analytic studies, preferably from more than one centre or research group;
Level 2-3. Evidence obtained from comparisons between times or places with or without the intervention;
Level 3. Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees.

It is clear that, in cancer treatment, there are many situations where improvement of clinical outcome is necessary.

Both preclinical and clinical studies have shown hyperthermia to be effective.

Clinical results

Strong proof of effectiveness of hyperthermia comes from clinical studies in which hyperthermia was used alone. A review of 14 such studies including a total of 343 patients, reported complete response rates varying from 0 to 40% (overall 13%) and partial response rates from 0 to 56%, with an overall objective response rate of 51% [8]. Three additional studies reported complete response rates of 11, 16 and 18% [9–11]. Since adequate heating the whole tumour volume is difficult except for superficially located small tumours, and in general the reported response duration is short, the use of hyperthermia alone is not recommended.

Relatively strong evidence comes from several studies on ‘matched lesions’: multiple lesions of the same patients were treated with radiotherapy, with or without hyperthermia. In some studies, the treatment was selected at random, in others the larger lesions received combination treatment. In all these studies, a higher complete response rate for combined treated lesions was demonstrated. A summation of the data from these studies (total 713 lesions) shows an increase in complete response rate from 31% to 67% [12].

Level I evidence

Level I evidence from randomised trials showing significantly better results following the addition of hyperthermia to other treatment modalities is summarised in Table I [13–32]. The majority of these studies were included in a previous review [33]. Publications concerning randomised trials were retrieved from PubMed, and information on additional studies came from meeting proceedings. Since the review was written, two more randomised studies have been published [30, 34]. Of the total 28 randomised trials, 19 showed significantly better results in the treatment arm with hyperthermia. The majority of this level I evidence concerns the addition of local hyperthermia to radiotherapy. The tumour types in which significant improvements were observed include head and neck tumours, melanoma, sarcoma, breast cancer, glioblastoma multiforme, rectum, bladder and cervix cancer, oesophageal cancer and various superficial tumours. Two studies have shown that local hyperthermia in addition to radiotherapy plus chemotherapy improved the results in oesophageal carcinoma. Perfusion hyperthermia in addition to chemotherapy, applied either pre- or postoperatively, improved
Table I. LEVEL I evidence from randomised trials showing significantly better results following combination of radiotherapy (RT), chemotherapy (CT), or RT plus CT with hyperthermia (HT), compared to the same treatment without HT. LHT, local HT; RHT, regional HT; WBHT, whole body HT; CR, complete response.

<table>
<thead>
<tr>
<th>Ref no.</th>
<th>Tumour</th>
<th>Treatment</th>
<th>Patients (lesions)</th>
<th>endpoint</th>
<th>Effect with HT</th>
<th>Effect without HT</th>
</tr>
</thead>
<tbody>
<tr>
<td>13, 14</td>
<td>Lymphnodes of head &amp; neck tumours</td>
<td>RT +/- LHT</td>
<td>41 (44)</td>
<td>CR rate</td>
<td>83%</td>
<td>41%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5-yr local control</td>
<td>69%</td>
<td>24%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5-yr survival</td>
<td>53%</td>
<td>0%</td>
</tr>
<tr>
<td>15</td>
<td>Melanoma</td>
<td>RT +/- LHT</td>
<td>70 (138)</td>
<td>CR rate</td>
<td>62%</td>
<td>35%</td>
</tr>
<tr>
<td>16</td>
<td>Breast</td>
<td>RT +/- LHT</td>
<td>306</td>
<td>2-yr local control</td>
<td>46%</td>
<td>28%</td>
</tr>
<tr>
<td>17</td>
<td>Glioblastoma multiforme</td>
<td>RT +/- LHT postoperative</td>
<td>68</td>
<td>Median survival</td>
<td>85 weeks</td>
<td>76 weeks</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2-yr survival</td>
<td>31%</td>
<td>15%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3-yr survival</td>
<td>30%</td>
<td>24%</td>
</tr>
<tr>
<td>18</td>
<td>Bladder, cervix and rectum</td>
<td>RT +/- LHT</td>
<td>298</td>
<td>CR rate</td>
<td>55%</td>
<td>39%</td>
</tr>
<tr>
<td>18</td>
<td>Cervix</td>
<td>RT +/- LHT</td>
<td>114</td>
<td>CR rate</td>
<td>83%</td>
<td>57%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3-yr survival</td>
<td>51%</td>
<td>27%</td>
</tr>
<tr>
<td>19</td>
<td>Rectum</td>
<td>RT +/- LHT preoperative</td>
<td>115</td>
<td>5-yr survival</td>
<td>36%</td>
<td>7%</td>
</tr>
<tr>
<td>20</td>
<td>Cervix</td>
<td>RT +/- LHT</td>
<td>64</td>
<td>CR</td>
<td>55%</td>
<td>31%</td>
</tr>
<tr>
<td>21</td>
<td>Various superficial</td>
<td>RT +/- LHT</td>
<td>92</td>
<td>Response</td>
<td>82%</td>
<td>63%</td>
</tr>
<tr>
<td>22</td>
<td>Cervix</td>
<td>RT +/- LHT</td>
<td>40</td>
<td>CR</td>
<td>85%</td>
<td>50%</td>
</tr>
<tr>
<td>23</td>
<td>Rectum</td>
<td>RT +/- LHT</td>
<td>14</td>
<td>Response</td>
<td>100%</td>
<td>20%</td>
</tr>
<tr>
<td>24</td>
<td>Bladder</td>
<td>RT +/- LHT preoperative</td>
<td>102</td>
<td>3-yr survival</td>
<td>94%</td>
<td>67%</td>
</tr>
<tr>
<td>25</td>
<td>Oesophagus</td>
<td>RT +/- LHT</td>
<td>125</td>
<td>3-yr survival</td>
<td>42%</td>
<td>24%</td>
</tr>
<tr>
<td>26</td>
<td>Rectum</td>
<td>RT +/- LHT preoperative</td>
<td>122</td>
<td>pCR</td>
<td>23%</td>
<td>5%</td>
</tr>
<tr>
<td>27</td>
<td>Bladder</td>
<td>CT +/- RHT preoperative</td>
<td>52</td>
<td>pCR</td>
<td>66%</td>
<td>22%</td>
</tr>
<tr>
<td>28</td>
<td>Bladder</td>
<td>CT +/- RHT postoperative</td>
<td></td>
<td>2-yr relapse free survival</td>
<td>~82%</td>
<td>~38%</td>
</tr>
<tr>
<td>29</td>
<td>Lung</td>
<td>CT +/- WBHT</td>
<td>44</td>
<td>Response</td>
<td>68%</td>
<td>36%</td>
</tr>
<tr>
<td>30</td>
<td>Soft tissue sarcoma</td>
<td>CT +/- LHT</td>
<td>341</td>
<td>Response</td>
<td>28.7%</td>
<td>12.6%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Local relapse free survival</td>
<td>45.3 months</td>
<td>23.7 months</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Disease free survival</td>
<td>31.7 months</td>
<td>16.2 months</td>
</tr>
<tr>
<td>31</td>
<td>Oesophagus</td>
<td>RT + CT +/- LHT</td>
<td>66</td>
<td>CR</td>
<td>25%</td>
<td>6%</td>
</tr>
<tr>
<td>32</td>
<td>Oesophagus</td>
<td>RT + CT +/- LHT preoperative</td>
<td>53</td>
<td>Palliation</td>
<td>70%</td>
<td>8%</td>
</tr>
</tbody>
</table>
results in bladder cancer. Whole body hyperthermia added to chemotherapy gave better results than chemotherapy alone for lung cancer.

Nine randomised studies failed to show a significant benefit from addition of hyperthermia. The following four studies showed a more than 10% higher (complete) response or local control rate with the addition of hyperthermia, but the numbers of patients were too small to make the difference statistically significant. In head and neck tumours, complete response rate was 58% following radiotherapy and 74% following radiotherapy plus hyperthermia [35]. In patients with multiple lesions, with inpatient randomisation, the response rate following radiotherapy was 7% and following combined treatment 47% [36]. In oesophageal cancer, pathological complete response rate after preoperative treatment with chemotherapy increased from 19% to 40% thanks to the addition of hyperthermia [37]. In cervical cancer, 18-months local control rate was 50% after radiotherapy and 70% after combined treatment [38]. Five studies showed smaller or no differences in clinical outcome between treatment with or without hyperthermia. Addition of hyperthermia to preoperative radiotherapy in breast cancer was reported to result in a significant improvement in local control rate, but only a tendency to improved survival was found, from 67% to 73% [39]. In gastric cancer, 5-year overall survival following preoperative radiotherapy was 45%, while it was 51% after combined treatment [40].

In three studies, which are further discussed in the paragraph ‘Importance of adequate local heating techniques’, inadequate heat delivery has been indicated as the cause of failure to achieving a beneficial effect from the addition of hyperthermia [34, 41–43].

Level II evidence

A few non-randomised studies comparing combined treatment to radiotherapy or chemotherapy alone in well-matched control groups have led to the acceptance of hyperthermia as part of standard care in The Netherlands and Germany.

In patients with thoracic wall invasion of malignant mesothelioma, addition of hyperthermia to radiotherapy resulted in considerably higher response and palliation rates, and much lower tumour regrowth and pain recurrence rates [44]. In children with a first relapse of germ cell tumours, addition of hyperthermia to chemotherapy resulted in much better disease free and overall survival [45–46].

Level III evidence

Two studies have led to the acceptance in The Netherlands of combined hyperthermia and cisplatin in patients with locoregional recurrences of cervix following radiotherapy. Simultaneous combination of cisplatin and hyperthermia resulted in 50% response [47–48], compared to 15% (maximum expected) with cisplatin alone. In six of 49 patients, the combination resulted in long-term disease free survival.

Further experience

Hyperthermia is used in some countries such as Japan to treat recurrent tumours, which are untreatable with any conventional treatment modalities and thus the patients would otherwise be denied further treatment. Because of the nature of the tumours, the results of such treatment are difficult to document by conventional means. However, it has been observed that hyperthermia of such tumours often causes noticeable retardation of tumour growth and confers significant palliative benefit, thereby improving quality of life of the patients [49]. The potential usefulness of hyperthermia for palliation and improvement of quality of life of patients with tumours untreatable with conventional treatment merits further investigation, especially in recurrent lung and liver cancers.

Interesting results were seen in patients with anal cancer. A randomised phase II trial, studying the effect of adding hyperthermia to radiotherapy and chemotherapy showed that with hyperthermia, patients had significantly fewer local recurrences and higher anorectal function preservation [50].

Importance of adequate local heating techniques

The results of the first two randomised studies performed in the USA were disappointing, as these studies failed to show a beneficial effect of adding hyperthermia to radiotherapy. Retrospectively, these negative results have been explained by the use of hyperthermia treatment techniques that were inadequate for the patients included in these studies [41–43]. In the study by Perez et al. [41–42] the more easily heated lesions (smaller than 3 cm in diameter) showed a difference in complete response rate (52% versus 39%), while the larger lesions did not (25% versus 27%). Recently, a randomised study on addition of hyperthermia to radiotherapy in patients with uterine cervical cancer also failed to show an advantage of hyperthermia [34]. This also appears a matter of inadequate heating techniques [51–52].
Over the years, the importance of adequate heating has become clear. A study on recurrent breast cancer showed that the complete response rate in tumours larger than 3 cm increased from 31% to 65% with the use of a better heating technique (433 MHz compared to 2450 MHz) in addition to re-irradiation [53]. It is not easy to translate measured temperatures directly into adequacy of heating technique. The measured temperature distribution depends strongly on number of thermometry sites and location of thermometry probes. Thermometry procedures differ between institutes and may, within the same institute, change over time. For example, within the afore mentioned study [53], the specific absorption rate (SAR) distribution was more homogeneous over the treatment volume when 433 MHz was used. Nevertheless, the measured temperatures were not better with the 433 MHz technique compared to the 2450 MHz technique, due to a difference in number of thermometry sites. In the five combined randomised trials on breast cancer [16], the improvement of tumour response due to addition of hyperthermia to radiotherapy and the measured temperatures were not related. This probably was also due to differences between the thermometry procedures.

A better measure for adequacy appears to be the use of SAR coverage of the treatment volume: the energy level that encompasses the volume at risk. Lee et al. [54] found that when the tumour volume was covered by 25% SAR, a higher complete response rate resulted than when SAR fell below 25%. Besides, SAR is a more attractive measure for adequacy since it can be prescribed. Nevertheless, many experimental and clinical studies have shown that higher temperature levels, converted into a large variety of hyperthermia dose descriptors, result in better outcomes. A recent study comparing the effect of a prospectively prescribed thermal dose of more than 10 CEM 43°C T90 with that of less than 1, demonstrated a considerable local control benefit from the higher dose [55]. Therefore, it is important to apply treatments with optimum available treatment techniques and with temperature measurements in or near the volume at risk to the maximum achievable temperature levels.

Cost of treatment

Toxicity

Normal tissue toxicity will result directly from hyperthermia when the tolerance limits are exceeded. Experimental studies have shown that most normal tissues are not damaged when the temperature over 1 hour treatment does not exceed 43°C [56]. Only nervous and gastro-intestinal tissues appear more sensitive. For the central nervous tissue, irreversible damage was found after treatment at 42°C–42.5°C for longer than 40–60 minutes [57]. Treatment of peripheral nervous tissue for >30 minutes at 44°C, or an equivalent dose, results in temporary functional loss, which recovers within 4 weeks [58]. Gastro-intestinal mucosa may be damaged by a one-hour treatment when the temperature exceeds 42°C [59]. During local hyperthermia, it is not always possible to avoid high temperatures in normal tissues adjacent to tumours, due to the heterogeneity of the temperature distribution, and the limited thermometry. The patient is not always able to feel temperature hot spots, e.g. when the target area has been subject to surgery in the past and sensitivity is disturbed. The undesirable side effect from superficial hyperthermia is usually a skin burn (in about 25% of the patients with recurrent breast cancer [16, 53–54], which can be healed with conservative treatment. During hyperthermia for deep-seated tumours, the skin is extensively cooled, through which the hot spots will develop in deeper tissues. A too high temperature in subcutaneous fat or muscle tissue results in a feeling of pressure, which is not always recognised by the patient. Thereby, patients may be reluctant to mention unpleasant sensations. Subcutaneous fat or muscle tissue burns usually do not cause much discomfort: the patient feels a subcutaneous lump, tender for a few days to maximum a few weeks, which disappears spontaneously. Subcutaneous fat burns were seen in 3–12% of the patients treated with deep hyperthermia. The risk of developing skin burns may be higher following treatment with a radiofrequency capacitive heating technique (5–16%) than with a radiative heating technique (0–3%) [18, 60–62]. However, pre-cooling of skin was found to significantly reduce the skin damage in capacitive heating [63]. The randomised studies did not show an increase in acute or late toxicity of radiotherapy. Whether the toxicity of chemotherapy is enhanced will depend on the temperature in the drug-sensitive tissues.

Toxicity from whole body hyperthermia depends on, besides temperature, the patient’s general condition, condition of organ systems, and the physiological conditions during the treatment [7]. Serious toxicity from hyperthermic perfusion with modern technology and proper choice of perfusate composition, flow rate and pressure, blood gas values, drug doses, temperature dose and scheduling, is limited [64]. During any application of hyperthermia it is important to avoid pressure on normal tissues. Pressure may hinder blood circulation, thereby increasing tissue temperature, and/or cause hypoxia. Either one of, or both these conditions will increase the risk of toxicity.
Economic aspects

The application of hyperthermia is relatively labour intensive. With local hyperthermia, the energy distribution and the resulting temperature distribution can only be partially monitored with interstitial placed temperature sensors. During treatment, the information given by the patient, especially on (painful) hot spots, is mandatory to prevent the development of thermal burns. The clinical staff have to be continuously alerted in interpreting both the measured temperature distribution and the symptoms mentioned by the patient, in order to appropriately adjust the applied energy distribution. Both whole body and perfusion hyperthermia are time-consuming procedures requiring appropriate equipment and skilled personal. Nevertheless, thanks to the large therapeutic gain achieved, the cost-effectiveness of hyperthermia appears acceptable. Within e.g. the Dutch randomised trial on intrapelvic tumours, the cost-per-life-year-gained for cervical cancer was less than €4000 [65].

Acceptance of hyperthermia

In several countries, hyperthermia has been accepted as a part of standard care for cancer for a number of years. The acceptance is often restricted to certain techniques (i.e. superficial treatments only), or to specified indications. However, hyperthermia has not yet been accepted as a standard cancer treatment modality in many countries. There appear to be several reasons for this lack of acceptance.

Quality of published studies

Problem. Many of the studies listed in Table I are relatively small studies, including less than 100 patients or lesions. Even with these small numbers, the results were sufficient to show a significant improvement by the addition of hyperthermia, because of the large gain. However, small studies are not easily accepted as the basis for new treatment guidelines by the medical community.

Solution. The institutes using hyperthermia have the obligation to perform more and larger high quality studies providing level I and level II evidence, and to publish these results. The quantity and quality of clinical studies of hyperthermia may be expected to improve when the treatment becomes available in more medical centres.

Lack of knowledge

Problem. Both the medical community and the general public are not well informed of hyperthermia and of what can be achieved with it. Scientific journals often reject manuscripts on the subject, stating that there is no interest for it.

Solution. Results of clinical studies should be reported more often and in a scientifically accepted format in radiation and medical oncology meetings, on both the national and international levels. Some basic knowledge of hyperthermia should be included in the teaching programme of medical students. The public should be informed more widely by the use of brochures and Internet. The web sites of national and international hyperthermia societies should be linked to each other.

Heating technique and thermometry

Problem. The application of hyperthermia is labour intensive and requires specifically trained staff. It is hard to know precise temperature distribution in tumour and normal tissues during heating. The tumour sites where hyperthermia can be adequately applied are limited. The number of institutions where hyperthermia treatment is available is limited. These last two problems are related: since the number of indications for the use of hyperthermia is limited, institutes are reluctant to invest in equipment and staff.

Solution. The efforts to develop better heating and thermometry techniques should be expanded. Further research should aim at improving existing techniques [66–68] and also developing new techniques or devices to be able to adequately heat more tumour sites. Much attention should be given to the development and verification of hyperthermia treatment planning systems [69–71] and to the development of non-invasive thermometry [72–73]. It appears to be possible to develop non-invasive thermometry systems utilising MRI, and to use this during hyperthermia treatment of patients [74]. The appropriate combination of such a thermometry system with heating equipment may vastly improve our capability to develop treatment planning programmes. With these tools the application of hyperthermia can, eventually, lead to real time treatment planning and a computer controlled feed-back system. This will make the treatment easier to apply, less labour intensive, and at the same time result in a better tolerance by patients.

Lack of quality control and staff training

Problem. The available quality assurance guidelines on how to apply hyperthermia cannot be translated directly into clinical practice. Demands concerning education of clinicians, physicists and technicians involved in the application of treatment are not formulated.
Solution. Quality assurance guidelines for each heating system and for each tumour site must be developed. Hyperthermia device companies should take an active part in this development. Educational programmes must be developed to train newcomers in the field. Users’ meetings must be organised often to exchange new experience and to maintain guidelines for quality assurance and education up-to-date.

Perception of unfavourable economic cost-benefit ratio

Problem. Hyperthermia requires investment in equipment and trained personnel. For the Dutch Deep Hyperthermia Trial, for example, the cost of a series of 5 treatments was calculated to be €6800. About half of this amount was for personnel, and one third for equipment. On the other hand, the maximum discounted cost-per-life-year-gained in cervical cancer patients, with the conservative assumption that a difference in eventual overall survival would be 11%, was only €3790, which is within the range calculated for accepted types of treatment.

Solution. Information concerning the real cost of hyperthermia should be made public. Hyperthermia investigators should provide more information on the costs of treatment. Since, in general, hospitalisation nor extensive laboratory tests nor treatment of side effects are necessary, the overall cost of hyperthermia probably is less than the cost of many other types of cancer treatment. As long as the indications for hyperthermia are limited, one centre could provide the therapy for near-by centres without the facility, which allows economically attractive investments.

Reimbursement for hyperthermia treatments is lacking, or insufficient

Problem. Reimbursement for hyperthermia treatment often is much lower than the real cost, or even completely lacking.

Solution. The insurance companies should be informed about the real costs of the treatment, and of the fact that the cost-benefit ratio is relatively favourable in comparison to other types of cancer treatment.

Lack of sufficient funding in general

Problem. Unlike the pharmaceutical companies, hyperthermia companies are small and lack financial resources for promotional activities and supporting clinical studies.

Solution. Several more recent results from hyperthermia may be of interest to pharmaceutical and/or biotech companies. Examples are the development of temperature sensitive liposomes for therapeutic or diagnostic applications [75–77], the exploration of heat shock proteins for triggering tumour immunogenecity [78–81], enhancement of gene expression with a heat shock promoter [82–85], the use of hyperthermia as an additional bone marrow purging modality [86–90], and improvement of the effect of tumour vasculature targeting agents [91–94].

Another way to raise funds to promote hyperthermia is to interest charitable foundations and/or companies which have programmes to support health improvements, to form a new international non-profit foundation to promote the benefits of hyperthermia, support cooperation in clinical trials, and support in establishing guidelines for quality assurance and training.

Conclusions and recommendations

Hyperthermia is the elevation of temperatures above the physiological level with the objective of achieving therapeutic gain.

Hyperthermia is a feasible, quantifiable and reproducible treatment modality. When added to other treatment modalities, hyperthermia results in relevant benefit to the patient.

When applying local hyperthermia, the aim must be to achieve temperatures as high as possible within the tumour volume, while normal tissue temperatures remain within tolerable levels.

Level I evidence for the benefit of hyperthermia when added to radiotherapy has been established for the following tumours: head and neck, melanoma, sarcoma, breast, glioblastoma multiforme, bladder, cervix, rectum, oesophagus and various superficial tumours.

Level I evidence has been established for the addition of hyperthermia to chemotherapy in tumours of the bladder, lung, and oesophagus (with radiotherapy as well).

Level II evidence has been established for the addition of hyperthermia to radiotherapy in malignant mesothelioma, and for addition to chemotherapy in pediatric germ cell tumours.

Level III evidence has been established in recurrent cervix carcinoma after previous radiation treatment when hyperthermia is added to chemotherapy.

Problems: Scientific problems concern patient selection, quality assurance, statistical design, assessment
of the thermal dose, and the need for better understanding of thermal biology.

Socioeconomic problems concern perception of the cost-benefit, reimbursement, lack of industry support and labour intensiveness, lack of medical community awareness and acceptance, and lack of public information.

**Solutions:** Achievement of more level I/II evidence, i.e. more well-designed randomised clinical trials, and high quality prospective trials with a well matched control group. Incorporation of translational research in clinical trials. Development of quality assurance guidelines per system and site. Improvement of thermal dosimetry, when feasible, use of non-invasive methods, and development of treatment techniques more friendly to users and patients. Extension of treatment techniques to other tumour sites. Expansion of relationships with pharmaceutical and biotech companies. More aggressive promotion of the benefits of hyperthermia in the medical community and to the general public.

**Recommendation**

To initiate the establishment of an international non-profit foundation to promote a wider use of hyperthermia and support improvement in quality control.

**References**


